Mark Kiel

Mark Kiel

Company: Genomenon

Job title: Chief Science Officer & Co- Founder

Seminars:

Chair’s Closing Remarks, End of Day Two & Networking 3:45 pm

We hope you enjoyed this year’s Biomarkers for Rare Disease SummitRead more

day: Day Two

Panel Discussion: Navigating Rare Disease Drug Development Regulation Pathways 12:30 pm

• With regulatory paths there is not a ‘one size fits all’ approach in rare disease, how can current pathways guide study planning across indications? • What expertise is needed to plan for regulatory filing? • How can CDx planning begin earlier when required for drug approval?Read more

day: Day Two

Chair’s Opening Remarks 9:20 am

Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.